Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis

<div>Efficacy classification models of the whole metabolism between H1975 and OR cells, in negative ion scan mode. (a) PCA 3D score plot of the H1975 and OR groups in negative ion scan mode (<i>n</i> = 6). (b) OPLS-DA score plot of the H1975 and OR groups in negative ion scan mode (<i>n</i> = 6). (c) A combination plot of loading S-plot and VIP- values for identifying differential metabolites.</div>

Journal of Oncology

fig3

Figure 3

Figure 3: Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis 

Figure 3 | Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis 